文献速递白血病

AMPK激活在急性髓系白血病中诱导免疫原性细胞死亡

AMPK activation induces immunogenic cell death in AML.
PubMed 文献 · Blood Adv · 2023-01-01

研究探讨小分子GSK621激活AMPK能否在急髓白血病中诱导免疫原性细胞死亡。结果显示GSK621使小鼠和人AML细胞表面暴露钙网蛋白,处理后的白血病细胞促进树突状细胞成熟并激活。在荷瘤同基因免疫健全小鼠中接种GSK621处理的白血病细胞具保护作用,该作用在去除CD4/CD8 T细胞后消失。

要点

  • GSK621激活AMPK后诱导小鼠和人AML细胞表面钙网蛋白暴露。
  • GSK621处理的白血病细胞促进骨髓来源树突状细胞活化与成熟。
  • 接种GSK621处理的白血病细胞的保护作用在去除CD4/CD8 T细胞后消失。

核心结论

  • GSK621激活AMPK可诱导免疫原性细胞死亡特征并促进抗白血病免疫应答。
  • 药理学AMPK激活是提高AML免疫治疗活性的新潜在靶点。

研究设计与样本

  • 研究使用小分子GSK621激活AMPK,在小鼠和人AML细胞及同基因免疫健全荷瘤小鼠中评估免疫原性细胞死亡特征和免疫应答。

主要发现

  • GSK621激活AMPK后诱导小鼠和人AML细胞钙网蛋白膜暴露。
  • GSK621处理的小鼠白血病细胞促进骨髓来源树突状细胞的活化和成熟。
  • 在移植AML的同基因免疫健全受者中,接种GSK621处理的白血病细胞具有保护作用。
  • 该保护作用在去除CD4/CD8 T细胞的受者中消失。

临床怎么用

  • 原文结论认为药理学AMPK激活是提高AML免疫治疗活性的新潜在靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survival of patients with acute myeloid leukemia (AML) can be improved by allogeneic hematopoietic stem cell transplantation (allo-HSCT) because of the antileukemic activity of T and natural killer cells from the donor. However, the use of allo-HSCT is limited by donor availability, recipient age, and potential severe side effects. Similarly, the efficacy of immunotherapies directing autologous T cells against tumor cells, including T-cell recruiting antibodies, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors are limited in AML because of multiple mechanisms of leukemia immune escape. This has prompted a search for novel immunostimulatory approaches. Here, we show that activation of adenosine 5'-monophosphate-activated protein kinase (AMPK), a master regulator of cellular energy balance, by the small molecule GSK621 induces calreticulin (CALR) membrane exposure in murine and human AML cells. When CALR is exposed on the cell surface, it serves as a damage-associated molecular pattern that stimulates immune responses. We found that GSK621-treated murine leukemia cells promote the activation and maturation of bone marrow-derived dendritic cells. Moreover, vaccination with GSK621-treated leukemia cells had a protective effect in syngeneic immunocompetent recipients bearing transplanted AMLs. This effect was lost in recipients depleted of CD4/CD8 T cells. Together, these results demonstrate that AMPK activation by GSK621 elicits traits of immunogenic cell death and promotes a robust immune response against leukemia. Pharmacologic AMPK activation thus represents a new potential target for improving the activity of immunotherapy in AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mondesir J, Ghisi M, Poillet L, et al. AMPK activation induces immunogenic cell death in AML. Blood Adv. 2023. PMID: 37903311. doi:10.1182/bloodadvances.2022009444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。